DrugPatentWatch Database Preview
Botulinum toxin type b - Biologic Drug Details
Summary for botulinum toxin type b
| Tradenames: | 1 |
| Patents: | 73 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for botulinum toxin type b |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for botulinum toxin type b |
Recent Clinical Trials for botulinum toxin type b
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Netherlands: Ministry of Health, Welfare and Sports | Phase 3 |
| Haukeland University Hospital | Phase 3 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Early Phase 1 |
Recent Litigation for botulinum toxin type b
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Halozyme, Inc. v. Lee | 2016-12-19 |
Pharmacology for botulinum toxin type b
| Mechanism of Action | Acetylcholine Release Inhibitors |
Company Disclosures: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-06-10 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-02-15 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for botulinum toxin type b
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112014016195 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0110458 | Start Trial |
| European Patent Office | 2056866 | Start Trial |
| China | 1933849 | Start Trial |
| Cyprus | 1115104 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for botulinum toxin type b
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015031 | Lithuania | Start Trial | PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326 |
| 00654 | Netherlands | Start Trial | PRODUCT NAME: BOTULINUM TOXINE, TYPE A; NAT. REGISTRATION NO/DATE: RVG 17379RVG 32957RVG 32958 20131029; FIRST REGISTRATION: |
| 2013000060 | Germany | Start Trial | PRODUCT NAME: BOTULINUMTOXIN; NAT. REGISTRATION NO/DATE: IE/H/0113/001-003/II/077 20130131; FIRST REGISTRATION: FINNLAND IE/H/0113/001-003/II/077-FI 20130116 |
| 00564 | Netherlands | Start Trial | PRODUCT NAME: BOTULINUM TOXINE; NAT. REGISTRATION NO/DATE: RVG 32957RVG 17379RVG 32958 2012270627; FIRST REGISTRATION: NL 25449 20110822 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
